Maximizing Drug Impact

Tris Pharmaceutical’s founder and CEO Ketan Mehta spoke with Pharmaceutical Executive about the company’s history and how it’s adapted over the decades. While the company initially focused on oral technology, it eventually broadened its scope and is working in areas such as pain management and addiction.

Mehta also discussed the ways that he ensures his company maximizes a drug’s impact and he experiences with a variety of regulatory environments.

Pharmaceutical Executive: What methods do you use to maximize drug impact?
Ketan Mehta: What we have seen is that often times, drugs are there. For example, in the ADHD space, there are often times drugs that are very effective, but there are certain issues.

You can have a sudden crash when the drug levels go down. That impacts the patient’s quality of life. You may need a booster dose if it doesn’t last long enough.

What we’ve done is double up the delivery system and focus on tiny particles that give continuous relief. This also takes the body’s natural mechanism to draw drugs out of particles and has sustained effect for the full duration of the drug’s release.

This offers symptom control throughout the day, or whenever the patient wants.

Other drugs are provided in liquid form. You calibrate based on the need given how the patient wants to take a drug. At the start of a therapy, you may want small doses because you don’t know the optimal dose yet. When you reach your right dose, you can continue on that.